Establishment and characterization of a new neuroendocrine carcinoma cell model

#3242

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Aim(s): We here report data on a new neuroendocrine carcinoma cell line (MS-18) from a high-grade rectal NEC.

Materials and methods: Expression of epithelial (E-Cad) and mesenchymal differentiation markers (N-Cad, SLUT, VIM), neuroendocrine markers (Synaptophysin (SP), NSE, Chromogranin A (CgA), CD56), tissue specific receptors (SSTR1-5), CXCR4 and the multidrug transporter ABCG2 was measured bei qRT-PCR, Western Blot and immunohistochemistry. The existing cell lines BON and QGP-1 served as controls.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,